Moderna (MRNA) Shares Drop 8% despite Impressive Result from Cancer Vaccine Phase 2 Trial
With the second phase concluded, the Phase 3 melanoma trial will begin soon.
Moderna Gains 7% as Cowen Upgrades MRNA Stock from Market Perform to Outperform
In addition to noting that Moderna will lead the RSV vaccine market, Cowen also referred to major opinion leaders’ belief in the pharmaceutical company competing in a “three-player vaccine market”.
Moderna Sees X3 Covid Vaccine Sales in Q1 2022, MRNA Stock Jumps 7%
Except for its recent jump, Moderna stock has been at the lows. The remarkable Q1 2022 performance may give Moderna a boost and help its stock to rebound.
MRNA Shares Up 9% as Moderna Starts Working on Booster Targeting Omicron Variant
According to Bancel, Moderna is working “with public health leaders around the world” to produce a booster to tackle the Omicron variant.
MRNA Stock Up 10% in Pre-market, Moderna to Release Omicron Variant Vaccine Early Next Year
Moderna said that it had mobilized hundreds of workers last week during the Thanksgiving holiday to start studying the deadly Omicron variant.
MRNA Stock Up 3%, Moderna Resubmits Application for Vaccine Booster Shots for All Adults
The anticipation of a booster shot approval has sent Moderna shares up.
MRNA Stock Down 18%, Moderna Reports Lower-than-Expected Q3 2021 Earnings
Moderna earned $7.70 per share for its latest quarter versus the $9.05 Refinitiv consensus estimate.
MRNA Stock Up Over 7%, Moderna Announces 2-in-1 Covid Vaccine Shot
The quest to update the Covid-19 vaccine by Moderna follows the resurgence of the virus under a new variant dubbed Delta.
Vaccine Stocks Soar in Wake of Renewed Coronavirus Fears
By
Tolu Ajiboye
Stocks of major vaccine makers rose on Monday amid renewed outbreak of COVID-19. Moderna CEO adds that vaccine makers have a huge opportunity for growth.
MRNA Stock Jumps 5% as Moderna Announces Better Vaccine Results against COVID-19 Delta Variant
Moderna’s mRNA vaccine has shown strong results with the delta, beta, and eta COVID-19 variants which have been the cause of concern over the last few months. The US pharma giant also secured emergency approval from the Government of India to use its vaccine for authorized purposes.
MRNA Stock Lost 6%, Moderna Booster Effective against COVID-19 Variants of Brazil and South Africa
Moderna’s booster shots combined with new COVID-19 vaccine variant is capable of creating more antibodies especially against the Brazilian and South African variant. Moderna will soon publish tests of its trials online. Besides, all eyes are on its earnings reports releasing later today.
Pfizer and Moderna COVID-19 Vaccines Proves Effective in Real-World Use after First Shot
The potential efficacy in the approved Pfizer-BioNTech and Moderna vaccines is spurring a delay in second dose administration by some nations, especially those with limited supplies of the jabs.
Moderna (MRNA) Stock Up 1% after Falling 9% in Reaction to Downgrade by BoA
In 2021, it is expected that Moderna will to generate $11 billion in revenue from its vaccine.
MRNA Stock Shoots 12% on Monday as Moderna Says Its Vaccine Will Work on New COVID Strains
Moderna’s top-executives have assured that the vaccine would be effective to a certain degree on the new mutations. However, they are willing to see more results under different conditions. Moderna has received a positive review from field experts as well!
MRNA Stock Down 3.58%, Moderna Studies Allergic Reactions to Its Vaccine
With the existence of huge global demand for the vaccine, Moderna stock is expected to rally further in the coming quarters.